Stay updated with breaking news from சாரா எல்டன் ஃபார். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate Neutralizing antibody responses were 10 times higher than people recovering from COVID-19 No related severe adverse events reported Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago s plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK s pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing. Immunogenicity, as measured by the neutralizing antibody titer, was high about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration. ....
Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate afp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afp.com Daily Mail and Mail on Sunday newspapers.
Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate Fast Track designation granted by US FDA Feasibility study initiated of a vaccine candidate to address emerging variants Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago s plant-derived COVID-19 vaccine candidate in combination with GSK s pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval from Canadian and US regulatory authorities to proceed with enrollment of healthy adults in the Phase 3 portion of the trial based on positive interim Phase 2 results. In parallel, Medicago has also initiated a feasibility study of a vaccine candidate to address the emerging COVID-19 variants. ....
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19 forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: GSK announces otilimab data for treatment of COVID investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.